Danish researchers working on new type of vaccine that targets disease causing bacterium

When we acquire diarrhea on a vacation, it is often caused by a bacterial infection. Now a Danish research team is working on a new type of vaccine design targeting the disease causing bacterium – if it works it may very well revolutionize not only the prevention of this disease, but also offer protection against other pathogens with a heavy disease burden such as Mycobacterium tuberculosis and antibiotic-resistant Staphylococcus aureus (MRSA).

See original article:
Danish researchers working on new type of vaccine that targets disease causing bacterium

Share

OncoTherapy Network discusses latest research on prostate cancer

UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on prostate cancer.

More here:
OncoTherapy Network discusses latest research on prostate cancer

Share

Team Spirit: A Glimpse Inside a Disease Management Meeting

Add a Comment By Peter Kingham, MD, Surgical Oncologist   |  Monday, December 15, 2014 Memorial Sloan Kettering’s top cancer specialists come together to consult on complex cases at weekly Disease Management Team meetings. read more

Read More:
Team Spirit: A Glimpse Inside a Disease Management Meeting

Share

Can Cells Be Turned from Cancerous to Normal?

2 comments By Julie Grisham, MS, Science Writer/Editor   |  Thursday, December 11, 2014 An experimental drug for blood cancers with certain genetic mutations is showing promise in early-stage trials.

Continue reading here:
Can Cells Be Turned from Cancerous to Normal?

Share

Latest version of iMedX Mobile app released for physicians

iMedX, a leading health information solutions company and a leader in medical documentation solutions, today announced that it released the next version of iMedX Mobile: an iOS app that enables highly secure, HIPAA-compliant medical documentation capture and access for physicians via iPhone or iPad anytime, anywhere.

See the original post:
Latest version of iMedX Mobile app released for physicians

Share

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

Read the original post:
Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Share